Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through Hims & Hers' U.S. telehealth platform, resolving a legal dispute that erupted last month. The arrangement expands distribution for two high-demand GLP-1 products, likely improving patient access and benefiting Hims & Hers' revenue and reach while removing a litigation overhang for Novo Nordisk.
Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through Hims & Hers' U.S. telehealth platform, resolving a legal dispute that erupted last month. The arrangement expands distribution for two high-demand GLP-1 products, likely improving patient access and benefiting Hims & Hers' revenue and reach while removing a litigation overhang for Novo Nordisk.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
